Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + capecitabine versus standard first-line therapy in elderly metastatic colorectal cancer
ChiCTR2400090630Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fruquintinib and capecitabine in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-free survival. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
fruquintinibcapecitabine
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2400090630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090630.